We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+7.66%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$455B
AUM Growth
+$26.6B
Cap. Flow
-$26.7B
Cap. Flow %
-5.87%
Top 10 Hldgs %
33.25%
Holding
16,292
New
1,466
Increased
6,223
Reduced
6,687
Closed
1,652

Top Buys

Rank Stock Value
1
QQQ icon
Invesco QQQ Trust
QQQ
+$645M
2
TMUS icon
T-Mobile US
TMUS
+$640M
3
T icon
AT&T
T
+$517M
4
HUM icon
Humana
HUM
+$481M
5
BSX icon
Boston Scientific
BSX
+$400M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$1.24B
2
AAPL icon
Apple
AAPL
+$755M
3
META icon
Meta Platforms (Facebook)
META
+$707M
4
CAT icon
Caterpillar
CAT
+$472M
5
AMD icon
Advanced Micro Devices
AMD
+$449M

Sector Composition

Rank Sector Weight
1 Healthcare 3.33%
2 Technology 3.2%
3 Financials 2.22%
4 Industrials 2.17%
5 Consumer Discretionary 2.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FATH
13776
CALL
DELISTED
Fathom Digital Manufacturing Corporation
FATH
$5.49K ﹤0.01%
505
-530
-51% -$12.4K
DNTH icon
13777
PUT
Dianthus Therapeutics
DNTH
$6.49B
$5.48K ﹤0.01%
431
+181
+72% +$2K
TCON
13778
PUT
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$5.48K ﹤0.01%
145
+90
+164% +$2.95K
ELVN icon
13779
PUT
Enliven Therapeutics
ELVN
$4.31B
$5.47K ﹤0.01%
250
-4,450
-95% -$90.5K
XPER icon
13780
PUT
Xperi
XPER
$329M
$5.46K ﹤0.01%
500
+160
+47% +$1.67K
TRIB
13781
CALL
Trinity Biotech
TRIB
$7.88M
$5.45K ﹤0.01%
+39
New +$6.03K
AWRE icon
13782
CALL
Aware
AWRE
$26.4M
$5.44K ﹤0.01%
3,200
-700
-18% -$1.2K
BIOX icon
13783
Bioceres Crop Solutions
BIOX
$28.7M
$5.42K ﹤0.01%
467
-80,463
-99% -$946K
VRA icon
13784
PUT
Vera Bradley
VRA
$93M
$5.39K ﹤0.01%
900
+100
+13% +$560
CCC
13785
PUT
CCC Intelligent Solutions
CCC
$4.11B
$5.38K ﹤0.01%
600
+500
+500% +$4.45K
ELME
13786
PUT
Elme Communities
ELME
$144M
$5.36K ﹤0.01%
300
-1,400
-82% -$25.6K
RAD
13787
DELISTED
Rite Aid Corporation
RAD
$5.34K ﹤0.01%
2,384
-464,330
-99% -$1.54M
CELG.RT
13788
Bristol-Myers Squibb Rights
CELG.RT
$224M
$5.33K ﹤0.01%
42,329
+5,192
+14% +$691
OCFT
13789
PUT
DELISTED
OneConnect Financial Technology
OCFT
$5.32K ﹤0.01%
+1,000
New +$6.74K
TEAD
13790
Teads Holding Co
TEAD
$66.8M
$5.31K ﹤0.01%
1,286
+69
+6% +$313
AKLI
13791
PUT
DELISTED
Akili Inc
AKLI
$5.28K ﹤0.01%
3,300
-1,600
-33% -$2.5K
DTEA
13792
DELISTED
DAVIDsTEA Inc. Common Stock
DTEA
$5.27K ﹤0.01%
10,953
-19,706
-64% -$17.3K
CELU icon
13793
CALL
Celularity
CELU
$20.1M
$5.27K ﹤0.01%
850
-50
-6% -$402
AIFU
13794
PUT
AIFU Inc
AIFU
$215M
$5.21K ﹤0.01%
2
-11
-85% -$34.2K
ACAXR
13795
DELISTED
Alset Capital Acquisition Corp Right
ACAXR
$5.19K ﹤0.01%
+22,574
New +$4.46K
PVLA
13796
PUT
Palvella Therapeutics
PVLA
$2.25B
$5.17K ﹤0.01%
66
+15
+29% +$1.74K
UAMY icon
13797
CALL
United States Antimony
UAMY
$825M
$5.17K ﹤0.01%
13,700
-38,400
-74% -$15.7K
RANI icon
13798
CALL
Rani Therapeutics
RANI
$89.5M
$5.16K ﹤0.01%
+1,000
New +$6.01K
LMAT icon
13799
CALL
LeMaitre Vascular
LMAT
$1.88B
$5.15K ﹤0.01%
+100
New +$4.86K
VRMEW
13800
DELISTED
VerifyMe, Inc. Warrant
VRMEW
$5.13K ﹤0.01%
23,308
+3,268
+16% +$624

Similar funds

Ken Griffin's Q1 2023 Portfolio in Review

As of Q1 2023, Ken Griffin held 16,292 positions worth $455B, up 6.2% from $428B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Ken Griffin withdrew a net $26.7B in Q1 2023, closing 1,652 positions and reducing 6,687 holdings. Its most notable exit was Restaurant Brands International, an estimated $93.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 3.3% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.

Against the trend, Ken Griffin opened a new position in Keurig Dr Pepper worth $238M.

  • Ken Griffin's largest Q1 2023 buy was Keurig Dr Pepper: 6,751,572 shares worth $238M.
  • Ken Griffin added most to Invesco QQQ Trust in Q1 2023, an estimated $645M increase.
  • Ken Griffin's biggest Q1 2023 reduction was Tesla, cutting an estimated $1.24B.
  • Ken Griffin fully exited Restaurant Brands International in Q1 2023, selling an estimated $93.3M.
  • Ken Griffin's ten largest holdings make up 33% of its $455B portfolio in Q1 2023.
  • Ken Griffin opened 1,466 new positions and closed 1,652 in Q1 2023.
  • Ken Griffin's portfolio value rose 6.2% quarter-over-quarter to $455B.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.